
Vilde Drageset Haakensen
- Researcher; MD, PhD
- +47 22 78 14 75, 986 69 297
Curriculum vitae (pdf) (docx format)
Clinical oncologist with extensive experience in translation research and clinical trials. Expertise in using whole genome analyses to characterize clinical cancer sample sets.
Current projects
- Molecular characterisation of lung squamous cell carcinomas
- Translational studies related to ongoing clinical trials:
Clinical trials:
1. DART - Durvalumab After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients
2. NIPU - Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma
Translational projects:
1. Gut microbiome profiling to identify alterations during immunotherapy and identify biomarkers for therapy response
2. Immune cell profiling of tumour and circulating body fluids to study immune response to therapy and identify predictive biomarkes.
3. Evaluation of dual PET to elucidate tumour cell composition in response to therapy - National PI of clinical trials:
a. PACIFIC-R
b. M7824 with cCRT in Unresectable Stage III NSCLC
c. KeyNote-012 (A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) - Local PI of clinical trials:
a. NARLAL2 (Novel Approach to Radio Therapy in Locally Advanced Lung Cancer)
b. KeyNote-867 (A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) - Main supervisor for Hanne Marte Nymoen and a PhD student to start in January 2021, co-supervisor for Henrik Horndalsveen
Original articles
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
Mol Oncol, 15 (2), 429-461
DOI 10.1002/1878-0261.12850, PubMed 33176066
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
Breast Cancer Res, 22 (1), 73
DOI 10.1186/s13058-020-01295-6, PubMed 32605588
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587
PathTracer: High-sensitivity detection of differential pathway activity in tumours
Sci Rep, 9 (1), 16332
DOI 10.1038/s41598-019-52529-3, PubMed 31704995
A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
J Mammary Gland Biol Neoplasia, 24 (2), 163-175
DOI 10.1007/s10911-018-09423-x, PubMed 30613869
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
Mol Oncol, 12 (6), 972-990
DOI 10.1002/1878-0261.12312, PubMed 29698574
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
Mol Oncol, 11 (10), 1361-1379
DOI 10.1002/1878-0261.12105, PubMed 28657165
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659
Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
Mol Oncol, 11 (2), 220-234
DOI 10.1002/1878-0261.12025, PubMed 28145100
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
Oncoimmunology, 5 (12), e1248015
DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
Subtype-specific micro-RNA expression signatures in breast cancer progression
Int J Cancer, 139 (5), 1117-28
DOI 10.1002/ijc.30142, PubMed 27082076
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
Nat Genet, 48 (4), 374-86
DOI 10.1038/ng.3521, PubMed 26928228
Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
Mol Oncol, 10 (1), 59-72
DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Am J Hum Genet, 97 (1), 22-34
DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
J Proteome Res, 13 (5), 2314-27
DOI 10.1021/pr401092y, PubMed 24669823
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
Genome Biol, 15 (8), 435
DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics
Cell Stem Cell, 13 (1), 117-30
DOI 10.1016/j.stem.2013.05.004, PubMed 23770079
Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes
ISRN Oncol, 2012, 450267
DOI 10.5402/2012/450267, PubMed 23227362
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
BMC Med Genomics, 4, 77
DOI 10.1186/1755-8794-4-77, PubMed 22044755
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
Proc Natl Acad Sci U S A, 109 (8), 2802-7
DOI 10.1073/pnas.1108781108, PubMed 21908711
Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
BMC Cancer, 11, 332
DOI 10.1186/1471-2407-11-332, PubMed 21812955
Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
Breast Cancer Res, 12 (4), R65
DOI 10.1186/bcr2632, PubMed 20799965
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
Int J Cancer, 118 (11), 2877-81
DOI 10.1002/ijc.21709, PubMed 16381016
Review articles
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
Mol Oncol, 4 (2), 98-118
DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370
Theses
Biology of the normal breast: relation to mammographic density and risk of breast cancer
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 1137, 1 b. (flere pag.)
BIBSYS 112766811, ISBN 978-82-8264-155-5